ライフサイエンスコーパス: influenza vaccination

1 ctiveness of HD influenza vaccination (vs SD influenza vaccination).

2 compare our findings to the situation after influenza vaccination.

3 denced by reports of suboptimal responses to influenza vaccination.

4 hemagglutinin (HA) stem may enable universal influenza vaccination.

5 data from five clinical studies of seasonal influenza vaccination.

6 possible SSTI associated with either AIT or influenza vaccination.

7 hanisms underlying differential responses to influenza vaccination.

8 ung and elderly individuals before and after influenza vaccination.

9 pronounced among patients with prior season influenza vaccination.

10 % protein) in an established murine model of influenza vaccination.

11 r in inducing protective immune responses to influenza vaccination.

12 e of stillbirth following seasonal trivalent influenza vaccination.

13 dy design, in assessing the effectiveness of influenza vaccination.

14 on therapy can mount effective responses to influenza vaccination.

15 nd T-cell responses before and 4 weeks after influenza vaccination.

16 ation could also enhance immune responses to influenza vaccination.

17 ffect of L. casei 431 on immune responses to influenza vaccination.

18 influenza-positive HCWs with fever and prior influenza vaccination.

19 After 21 d, subjects received the seasonal influenza vaccination.

20 studies suggest decreased risks of CVDs with influenza vaccination.

21 r (aged >/=65 years) adults before and after influenza vaccination.

22 influenza, had lower odds of having received influenza vaccination.

23 recipients before and 1 month after seasonal influenza vaccination.

24 sponses get boosted in humans after seasonal influenza vaccination.

25 ple roles in inducing protective immunity to influenza vaccination.

26 ng the importance of primary prevention with influenza vaccination.

27 ression on recall T- and B-cell responses to influenza vaccination.

28 in depth both at baseline and in response to influenza vaccination.

29 is several times greater than that following influenza vaccination.

30 lly significant increase in rate of seasonal influenza vaccination.

31 duction and maintenance of these cells after influenza vaccination.

32 lthy adults prior and subsequent to seasonal influenza vaccination.

33 ce the immunogenicity and efficacy of annual influenza vaccination.

34 sideration of the optimal timing of seasonal influenza vaccination.

35 All children had a history of prior influenza vaccinations.

36 vents was similar after the first and second influenza vaccinations.

37 za-infected HCWs, 20 had previously received influenza vaccination, 18 had declined the vaccine, and

38 visit (60.9% vs. 55.2%; P < .001) but not an influenza vaccination (22.1% vs. 21.5%; P = .70).

39 likely than non-IC patients to have received influenza vaccination (53% vs 46%; P < .001), and ~85% o

40 ompared with the burden already prevented by influenza vaccination, a 5% absolute VE increase would h

41 ompared with the burden already prevented by influenza vaccination, a 5% absolute VE increase would p

42 e platforms have been developed for seasonal influenza vaccination: a recombinant HA vaccine produced

43 Despite the benefits of yearly influenza vaccination, accumulating evidence suggests th

44 ed hazard ratio, 1.04; 95% CI, 0.68-1.58) or influenza vaccination (adjusted hazard ratio, 1.10; 95%

45 All influenza vaccinations administered between 1 August and

46 nationwide sample of Medicare beneficiaries, influenza vaccination among adults aged 18-64 years was

47 ht to determine if the racial differences in influenza vaccination among nursing home (NH) residents

48 s models to estimate the association between influenza vaccination and all-cause mortality before inf

49 Influenza vaccination and antiviral administration could

50 the need for additional studies on maternal influenza vaccination and autism.

51 fic antibodies, as well as macrophages, upon influenza vaccination and challenge.

52 t circulating TFR frequencies increase after influenza vaccination and correlate with anti-flu Ab res

53 o guide and prioritize interventions such as influenza vaccination and HIV prevention in low- and mid

54 ral strains could reduce the need for yearly influenza vaccination and increase our preparedness for

55 ion could reveal a similar effect for active influenza vaccination and influence CIML NK cell effecto

56 We analyzed influenza vaccination and influenza severity using Influ

57 Recent receipt of seasonal influenza vaccination and older age were associated with

58 owledge exists about the association between influenza vaccination and outcome in patients with HF.

59 dies have evaluated the relationship between influenza vaccination and pneumonia, a serious complicat

60 sights regarding the serological response to influenza vaccination and raise questions about the adde

61 reafter, L. casei 431) on immune response to influenza vaccination and respiratory symptoms in health

62 on days 0 to 1, adjusted for age group, past influenza vaccination and simultaneous receipt of select

63 Influenza vaccination and statin prescription statuses o

64 r results demonstrate the benefit of current influenza vaccination and the need for improved vaccines

65 aimed to investigate the association between influenza vaccination and the risk of CVDs.

66 duals who did not attend the practice for an influenza vaccination and there was a limited representa

67 onditions should be considered when planning influenza vaccination and treatment strategies.

68 d pressure screening, cholesterol screening, influenza vaccination, and annual dental visit.

69 cteristics, pre-existing medical conditions, influenza vaccination, and other factors.

70 atment, adjusting for underlying conditions, influenza vaccination, and pregnancy trimester.

71 larly, the serological responses to seasonal influenza vaccination are also determined largely by non

72 al media data suggest that SSTI from AIT and influenza vaccination are equally rare events.

73 dies in which the fetal benefits of maternal influenza vaccination are evaluated by estimating detect

74 Rates of seasonal influenza vaccination are modestly but significantly low

75 ts suggest that allergic reactions following influenza vaccination are not necessarily related to egg

76 Influenza vaccination averted 1 in 25 (3.8%; 95% CI, 3.6

77 Influenza vaccination averted substantial influenza-asso

78 aluate the benefits to the fetus of maternal influenza vaccination because the causal benefit of vacc

79 serological and cellular immune responses to influenza vaccination being impaired in HIV-infected ind

80 The adjusted odds ratio of prior influenza vaccination between cases and controls was 0.4

81 on the components of the immune response to influenza vaccination but reduced the duration of upper

82 Pregnant women are prioritized for seasonal influenza vaccination, but the evidence on the risk of i

83 recommended that healthcare providers offer influenza vaccination by October, if possible.

84 The pooled OR of developing CVDs after influenza vaccination by pooling case-control studies wa

85 ark from pregnancies overlapping the A(H1N1) influenza vaccination campaign in Denmark, from November

86 Because influenza vaccination can be poorly effective some years

87 HCP influenza vaccination can enhance patient safety.

88 Some studies suggest that maternal influenza vaccination can improve birth outcomes.

89 Influenza vaccination can potentially reduce the inciden

90 Influenza vaccinations can protect against disease but m

91 During the acute response to influenza vaccination, CD19(pos), CD19(low), and CD19(ne

92 ble persons aged >=65 years (y) attending an influenza vaccination clinic were offered a free heart r

93 entify posts related to AIT and, separately, influenza vaccination (comparator procedure).

94 ureus exhibited a reduced immune response to influenza vaccination compared with noncolonized partici

95 re to circulating human influenza viruses or influenza vaccination confers immunity to H7N9 strains.

96 sed antibody response compared with standard influenza vaccination consisting of a single dose.

97 examined the association between county-wide influenza vaccination coverage among 520 229 younger adu

98 During the intervention, influenza vaccination coverage among elementary students

99 Increasing influenza vaccination coverage among young children and

100 Influenza vaccination coverage derived from data from th

101 potential for self-administration can expand influenza vaccination coverage in developing countries.

102 we estimated intervention impacts on student influenza vaccination coverage, school absenteeism, and

103 ns with moderately high background levels of influenza vaccination coverage, SLIV programs are associ

104 n (SLIV) intervention that aimed to increase influenza vaccination coverage.

105 At 7 d after inactivated influenza vaccination, cTfh correlated with influenza va

106 Influenza vaccination dates were confirmed by medical re

107 quently underperform in response to seasonal influenza vaccination, despite virologic control of HIV.

108 Influenza vaccination during 2013-14 influenza season at

109 udy has investigated the association between influenza vaccination during pregnancy and ASD.

110 Using an RCT as a vaccine probe, influenza vaccination during pregnancy decreased all-cau

111 Despite strong evidence that maternal influenza vaccination during pregnancy is safe, uptake o

112 evidence indicates that seasonal inactivated influenza vaccination during pregnancy protects both the

113 cination during pregnancy is safe, uptake of influenza vaccination during pregnancy remains low.

114 (0.7%) mothers and 45 231 (23%) received an influenza vaccination during pregnancy.

115 niors (65+ years) after high-risk groups for influenza vaccination during times of limited vaccine su

116 niors (65+ years) after high-risk groups for influenza vaccination during times of limited vaccine su

117 Clinicians should ensure high rates of influenza vaccination, especially in those with underlyi

118 e approved in the United States for seasonal influenza vaccination every year.

119 n suggests that evaluating immunogenicity of influenza vaccination exclusively by hemagglutination in

120 timate increased to 34% after correcting for influenza vaccination exposure misclassification.

121 Our results support recommendations for influenza vaccination for patients with cancer.

122 Evidence establishing effectiveness of influenza vaccination for prevention of severe illness i

123 be considered by policy makers recommending influenza vaccinations for elderly people.

124 Influenza vaccination gave meaningful protection against

125 Influenza vaccination gave meaningful protection against

126 splantation for annual trivalent inactivated influenza vaccination greater than 3 to 6 months post-ki

127 Influenza vaccination guidelines have recommended that p

128 The effectiveness of trivalent influenza vaccination has been confirmed in several stud

129 ssible small increased risk of GBS following influenza vaccination has been identified, but the magni

130 Antibody waning following influenza vaccination has been repeatedly evaluated, but

131 immune response of transplant recipients to influenza vaccination has been studied in detail.

132 Influenza vaccination has the potential to reduce the in

133 Our findings underscore the value of influenza vaccination, highlighting that vaccines measur

134 e not well understood for 2-dose inactivated influenza vaccination (IIV) schedules in autologous haem

135 not (n = 29) immediately before inactivated influenza vaccination (IIV), 7 d after vaccination, and

136 fication of receipt of trivalent inactivated influenza vaccination (IIV-3).

137 ceived a standard-dose trivalent inactivated influenza vaccination (IIV3) at enrollment, and either t

138 results suggest that most BMPCs generated by influenza vaccination in adults are short-lived.

139 e for circulating Tfh cells (cTfh) following influenza vaccination in adults, but cTfh have not been

140 ological evidence base for continuing annual influenza vaccination in adults.

141 nza vaccine (LAIV) is recommended for annual influenza vaccination in children from age 2 years.

142 The population effects of influenza vaccination in children have not been extensiv

143 The pooled OR of decreasing CVDs after influenza vaccination in cohort studies was 0.89 (95% CI

144 support the current recommendation of annual influenza vaccination in HCWs.

145 teady-state and during the acute response to influenza vaccination in healthy donors, we identify the

146 Seasonal influenza vaccination in humans primarily stimulates pre

147 ibe molecular signatures driving immunity to influenza vaccination in humans.

148 ty of germinal centre B cell responses after influenza vaccination in humans.

149 ibody specificity and cross-reactivity after influenza vaccination in individuals with different infl

150 proved understanding of the ADCC response to influenza vaccination in older adults is required.

151 These results support the importance of influenza vaccination in older adults, who account for m

152 effectiveness decline within 6 months after influenza vaccination in older adults.

153 Semiannual influenza vaccination in older residents of tropical cou

154 which we applied to human plasmablasts after influenza vaccination in order to characterize transcrip

155 vidence-based preventive strategies to offer influenza vaccination in patients with CVDs.

156 used to estimate the adjusted odds ratio of influenza vaccination in people with, compared to those

157 re is uncertainty about the effectiveness of influenza vaccination in persons with asthma and its imp

158 s add to the evidence base for the safety of influenza vaccination in pregnancy.

159 tional study in Laos to assess the effect of influenza vaccination in pregnant women on birth outcome

160 We estimated the effectiveness of documented influenza vaccination in preventing laboratory-confirmed

161 The pooled RR of developing CVDs after influenza vaccination in RCT studies was 0.55 (95% CI 0.

162 Here, we analyze CD4 T cell responses to influenza vaccination in subjects who differ in their va

163 is study, we analyze CD4 T-cell responses to influenza vaccination in subjects who differ in their va

164 been implicated in poor Ab responsiveness to influenza vaccination in the elderly, most of whom are C

165 Recent studies suggest that influenza vaccination in the previous season may influen

166 Maternal influenza vaccination in the second or third trimester w

167 isk among children whose mothers received an influenza vaccination in their first trimester, but the

168 Safety and immunogenicity data of seasonal influenza vaccination in transplanted patients (Tps) are

169 .77, p = 0.001), and 66% compared to 59% had influenza vaccinations in the past year (odds ratio 1.35

170 /ethnicity, tobacco use, chronic conditions, influenza vaccination, influenza antiviral medication, a

171 ng evidence that reduced VE after sequential influenza vaccination is a real phenomenon.

172 Although antenatal influenza vaccination is an important public health inte

173 We propose a radical change in the way influenza vaccination is approached, in which a recombin

174 This study sought to determine whether influenza vaccination is associated with improved long-t

175 CD4 T cell formation following cold-adapted influenza vaccination is boosted when Ag is administered

176 Maternal influenza vaccination is increasingly recognized to prot

177 Influenza vaccination is less effective in elderly as co

178 Given that influenza vaccination is now widely recommended in the U

179 infection history in targeting and promoting influenza vaccination is predicted to be a highly effect

180 Although influenza vaccination is recommended for all adults annu

181 Seasonal influenza vaccination is recommended for patients with c

182 R, a booster strategy 5 weeks after standard influenza vaccination is safe and effective and induces

183 Influenza vaccination is safe even in children with hist

184 Influenza vaccination is the primary approach to prevent

185 th maternal and infant morbidity, and annual influenza vaccination is warranted.

186 sequencing to dynamically track responses to influenza vaccination, Jackson et al. find evidence of c

187 For persons with asthma, influenza vaccination may be effective in both reducing

188 Influenza vaccination may benefit young children and HIV

189 This study shows that influenza vaccination may have a clinical benefit in all

190 observational studies suggest that previous influenza vaccination may influence the immunogenicity a

191 from some recent studies have suggested that influenza vaccination might also prevent adverse pregnan

192 Some studies suggest that influenza vaccination might be protective against severe

193 0 years ago, it was observed that sequential influenza vaccination might lead to reduced vaccine effe

194 an OVA immunization model and a preclinical influenza vaccination mouse model.

195 Our analyses suggest that influenza vaccinations not only prevent infection agains

196 suggests that the large fetal benefits from influenza vaccination observed in epidemiologic studies

197 The available evidence suggests that influenza vaccination of children confers indirect prote

198 We investigated whether influenza vaccination of children would protect them and

199 Influenza vaccination of healthcare personnel (HCP) is r

200 black NH residents and a white-black gap in influenza vaccination of NH residents (N=2,233,392) of a

201 It is unknown whether influenza vaccination of nonelderly adults confers addit

202 Yet the impact of repeated annual influenza vaccination on both cross-reactive CD4+ and CD

203 nt study does support the protective role of influenza vaccination on CVDs events.

204 ny contrasting ideas on the effectiveness of influenza vaccination on CVDs.

205 We investigated the effect of influenza vaccination on disease severity in adults hosp

206 Our findings show a modest effect of influenza vaccination on disease severity.

207 Here we compare the impact of repeat influenza vaccination on hemagglutination inhibition (HI

208 network to further investigate the effect of influenza vaccination on influenza severity in adults ag

209 ough June 2012 to evaluate the effect of HCP influenza vaccination on mortality, hospitalization, and

210 pothesis, we examined the effect of seasonal influenza vaccination on NK cell function and phenotype

211 We examined the influence of influenza vaccination on reducing antibiotic prescriptio

212 analyzed the effect of inactivated trivalent influenza vaccination on the prevalence of influenza RVI

213 ecent reports of a negative impact of serial influenza vaccination on vaccine effectiveness (VE) rais

214 he probability of influenza RVI progression: influenza vaccination (OR 0.12, 95% confidence interval

215 B-cell responses elicited following repeat influenza vaccinations over multiple seasons have not be

216 reinforce current recommendations for annual influenza vaccination, particularly those at greatest ri

217 middle-income countries have adopted routine influenza vaccination policies for children and, where p

218 mework to evaluate the cost-effectiveness of influenza vaccination policies in developing countries a

219 We evaluated such influenza vaccination policies through small-world conta

220 , and for therapeutic applications including influenza vaccination, polio vaccination, and diabetes a

221 These data are a step forward in making oral influenza vaccination possible.

222 We estimated that influenza vaccination prevented 7.1 million (95% CrI, 5.

223 Influenza vaccination prevented an estimated 4.4 million

224 Pneumococcal and influenza vaccinations prevented further transmission.

225 Maternal influenza vaccination prevents influenza illness in both

226 target age groups when extending a seasonal influenza vaccination programme of at-risk individuals t

227 cility 90 days or more before commencing the influenza vaccination programme).

228 Influenza vaccination programmes around the world are st

229 the preventive value of maternal and infant influenza vaccination programmes.

230 t activation of the RIG-I pathway along with influenza vaccination programs the innate immunity to in

231 To understand factors that may impact influenza vaccination programs, we developed a model to

232 may further inform the benefits of maternal influenza vaccination programs.

233 target groups, timing, and cost of national influenza vaccination programs.

234 These data demonstrate that influenza vaccination promotes the prevalence of relevan

235 emonstrate that the early B-cell response to influenza vaccination, quantified by the frequency of in

236 Antibody titers decrease with time following influenza vaccination, raising concerns that vaccine eff

237 With influenza vaccination rates in the United States recentl

238 nal and infant mortality/morbidity; however, influenza vaccination rates of pregnant women remain und

239 ons to vaccinate surgical inpatients against influenza, vaccination rates remain low in this populati

240 These findings favor continuation of annual influenza vaccination recommendations, particularly in o

241 Despite 38% VE, influenza vaccination reduced a substantial burden of in

242 Influenza vaccination reduced influenza virus infection

243 Influenza vaccination reduced the risk of ARI associated

244 ng traditional research designs suggest that influenza vaccination reduces hospitalizations and morta

245 e matched by social media platform to 25,126 influenza vaccination-related posts.

246 5% CI, 0.007%-0.048%) indicative of possible influenza vaccination-related SSTI.

247 Effective annual influenza vaccination requires frequent changes in vacci

248 3,201 single cells from healthy high and low influenza vaccination responders revealed that our signa

249 Application of QuSAGE meta-analysis to influenza vaccination response shows it can detect signi

250 BCG vaccination prior to influenza vaccination results in a more pronounced incre

251 al technology and pulse palpation during the influenza vaccination season.

252 Screening was conducted over two influenza vaccination seasons, 2017-2018 and 2018-2019,

253 t that differences in cross-reactivity after influenza vaccination should be expected in individuals

254 D are colonized with S aureus, intramuscular influenza vaccination should be given preference in thes

255 om the updated recommendations for 2020-2021 influenza vaccination should generally be considered ess

256 We evaluated a city-wide school-located influenza vaccination (SLIV) intervention that aimed to

257 School-located influenza vaccination (SLV) programs can efficiently imm

258 Residents' influenza vaccination status (vaccinated, refused, and n

259 ithout laboratory-confirmed influenza and by influenza vaccination status among subjects with influen

260 Influenza vaccination status was ascertained by vaccine

261 HCWs also reported symptoms and influenza vaccination status, and underwent temperature

262 r age, sex, season, influenza diagnosis, and influenza vaccination status.

263 Influenza vaccination strategies have targeted elderly i

264 Universal influenza vaccination strategies should be capable of pr

265 DCC Abs and their potential role in improved influenza-vaccination strategies.

266 duction of memory T- and B-cell responses to influenza vaccination supports the recommendation to vac

267 in inducing protective antibody responses to influenza vaccination than CD4 T cell-deficient mice.

268 Finally, after influenza vaccination, the proportion of influenza-speci

269 to innate cytokines were also enhanced after influenza vaccination; this was associated with prolifer

270 accination, as well as pre-pandemic seasonal influenza vaccination to elucidate the effect of the adj

271 ge in a community-based, randomized prenatal influenza vaccination trial in Nepal with weekly infant

272 sits and antibiotic prescriptions averted by influenza vaccination using estimates of VE, coverage, a

273 five adults longitudinally before and after influenza vaccination using high-throughput antibody rep

274 Effectiveness of 2014-2015 influenza vaccination varied by genetic group of influen

275 Effectiveness of 2014-2015 influenza vaccination varied by influenza A(H3N2) virus

276 Influenza vaccination, verified through record review.

277 Here, we report that unadjuvanted seasonal influenza vaccination via intratumoral, but not intramus

278 We assessed the relative effectiveness of HD influenza vaccination (vs SD influenza vaccination).

279 The white-black gap in influenza vaccination was 9.9 percentage points.

280 Influenza vaccination was also associated with a lower l

281 Influenza vaccination was ascertained from physician and

282 A multivariate analysis showed that influenza vaccination was associated with a lower preval

283 In patients with HF, influenza vaccination was associated with a reduced risk

284 Influenza vaccination was associated with a reduction in

285 During 2010-2011, influenza vaccination was associated with a significant

286 010-2011 and 2011-2012 US influenza seasons, influenza vaccination was associated with a three-quarte

287 During the studied influenza seasons, influenza vaccination was at least modestly effective in

288 Maternal influenza vaccination was determined using primary care

289 Of patients for whom data was available, influenza vaccination was reported in 3289 (28.7%) of 11

290 trimester-specific analyses, first-trimester influenza vaccination was the only period associated wit

291 : Use of dissolvable microneedle patches for influenza vaccination was well tolerated and generated r

292 To measure student influenza vaccination, we conducted cross-sectional surv

293 nts enrolled in a clinical trial of maternal influenza vaccination, we estimate incidence of RSV-asso

294 wing BCG vaccination, nonspecific effects of influenza vaccination were also observed, with modulatio

295 Effects of repeat influenza vaccination were consistent with the ADH and m

296 ously reported molecular signatures of human influenza vaccination were derived from a single age gro

297 ancy modifies the humoral immune response to influenza vaccination will aid in maximizing vaccine eff

298 Seasonal influenza vaccination with either LAIV4 or IIV3 was the

299 All patients received influenza vaccination without an allergic reaction.

300 influenza vaccination without an allergic reaction.